ADC Therapeutics Announces Abstracts to be Presented at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO 2022)
ADC Therapeutics (NYSE: ADCT) announced positive results from the initial safety run-in of the LOTIS-5 Phase 3 trial, showing a 75% overall response rate and a 40% complete response rate for ZYNLONTA in combination with rituximab for patients with relapsed or refractory diffuse large B-cell lymphoma. The results will be presented at the SOHO 2022 conference in Houston, Texas from September 28-October 1, 2022. Additionally, the company plans to showcase pivotal Phase 2 data for Camidanlumab Tesirine (Cami) during the event.
- LOTIS-5 trial shows 75% overall response rate.
- 40% complete response rate in the safety run-in phase.
- No new safety signals reported, indicating a favorable safety profile.
- None.
Initial safety run‐in results from
Cami pivotal Phase 2 data to be highlighted in encore oral and poster presentations
LAUSANNE,
“We are looking forward to sharing the encouraging initial safety run-in results from our
The 20 patients in the safety run‐in were a median age of 74.5 years (range 35‐93) and received a median of 1 previous therapy (range 1‐6). As of the
-
The overall response rate by central review was 15/20 (
75% ). A total of 8/20 (40% ) and 7/20 (35% ) patients attained complete response and partial response, respectively. -
The most common all‐grade TEAEs, regardless of the relationship to the study treatment, were rash (5 [
25% ]), fatigue (4 [20% ]), and increased gamma-glutamyl transferase (4 [20% ]). The most common grade ≥3 TEAEs were increased gamma-glutamyl transferase (3 [15% ]), increased alanine aminotransferase (2 [10% ]), and neutropenia (2 [10% ]).
These data will be presented in the following poster:
Initial Safety Run‐In Results of the Phase 3 LOTIS‐5 Trial: Novel Combination of Loncastuximab Tesirine With Rituximab (Lonca‐R) Versus Immunochemotherapy in Patients With R/R DLBCL
Poster Number: ABCL-320
Details of ADC Therapeutics’ other poster presentations:
A Phase 2, Open-Label Study of Loncastuximab Tesirine in Combination with Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Patients with Diffuse Large B-cell Lymphoma (DLBCL) (
Poster Number: ABCL-272
Health-Related Quality of Life and Tolerability in Patients With/Without Skin Toxicity During Loncastuximab Tesirine Treatment in a Phase 2 Clinical Trial (
Poster Number: ABCL-316
Long-term survival projections of loncastuximab tesirine-treated patients in relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) (Encore data, first time as presentation)
Poster Number: ABCL-334
Camidanlumab Tesirine: Updated Efficacy and Safety in an Open-Label, Multicenter, Phase 2 Study of Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL) (Encore)
Poster Number: HL-339
All posters will be presented on
Details of ADC Therapeutics’ oral presentation:
Camidanlumab Tesirine: Updated Efficacy and Safety in an Open-Label, Multicenter, Phase 2 Study of Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL) (Encore)
Date and Time:
Location: Grand Ballroom G-L, 4th floor
Presenter:
Session XII: Hodgkin Lymphoma
About ZYNLONTA® (loncastuximab tesirine-lpyl)
ZYNLONTA® is a CD19-directed antibody drug conjugate (ADC). Once bound to a CD19-expressing cell, ZYNLONTA is internalized by the cell, where enzymes release a pyrrolobenzodiazepine (PBD) payload. The potent payload binds to DNA minor groove with little distortion, remaining less visible to DNA repair mechanisms. This ultimately results in cell cycle arrest and tumor cell death.
The
ZYNLONTA is also being evaluated as a therapeutic option in combination studies in other B-cell malignancies and earlier lines of therapy.
About Camidanlumab Tesirine (Cami)
Camidanlumab tesirine (Cami) is an antibody drug conjugate (ADC) comprised of a monoclonal antibody that binds to CD25 (HuMax®-TAC, licensed from Genmab A/S), conjugated to the pyrrolobenzodiazepine (PBD) dimer payload, tesirine. Once bound to a CD25-expressing cell, Cami is internalized into the cell where enzymes release the PBD-based payload, killing the cell. This applies to CD25-expressing tumor cells and also to CD25-expressing Tregs. The intra-tumoral release of its PBD payload may also cause bystander killing of neighboring tumor cells, and PBDs have also been shown to induce immunogenic cell death. All of these properties of Cami may enhance immune-mediated anti-tumor activity.
Cami is being evaluated in a pivotal Phase 2 clinical trial in patients with relapsed or refractory Hodgkin lymphoma and a Phase 1b clinical trial as monotherapy and in combination with pembrolizumab in solid tumors.
About
ADC Therapeutics’ CD19-directed ADC ZYNLONTA (loncastuximab tesirine-lpyl) is approved by the FDA for the treatment of relapsed or refractory diffuse large b-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents. Cami (camidanlumab tesirine) is being evaluated in a pivotal Phase 2 trial for relapsed or refractory Hodgkin lymphoma and in a Phase 1b clinical trial for various advanced solid tumors. In addition to ZYNLONTA and Cami,
ZYNLONTA® is a registered trademark of
View source version on businesswire.com: https://www.businesswire.com/news/home/20220921005889/en/
Investors
Eugenia.Litz@adctherapeutics.com
+44 7879 627205
amanda.hamilton@adctherapeutics.com
+1 917-288-7023
Media
maryann.ondish@adctherapeutics.com
+1 914-552-4625
Source:
FAQ
What were the initial results of the LOTIS-5 Phase 3 trial for ADCT?
When will the results of the LOTIS-5 trial be presented?
What does the LOTIS-5 trial evaluate?
What is ADC Therapeutics' stock symbol?